Core Viewpoint - Goldman Sachs raised its earnings per share forecast for WuXi Biologics (2269.HK) for the years 2023 to 2027 by 11.9% to 15.9%, reflecting better-than-expected gross margin improvement [1] Group 1 - Target price increased from HKD 25.6 to HKD 29.3, maintaining a price-to-earnings ratio target of 23 times, with a neutral rating [1] - The company's mid-term gross margin expanded by 3.6 percentage points to 42.7%, driven by reduced employee stock compensation, increased milestone revenue recognition from R&D, and improved utilization of new capacity, offsetting losses from the Ireland project [1] - Management expects gross margin improvement to continue in the second half of the year, based on operational enhancements and increased capacity utilization, with a long-term gross margin target of 50%, and the Singapore facility's gross margin expected to reach approximately 45% [1]
大行评级丨高盛：上调药明生物目标价至29.3港元 管理层料下半年毛利率续改善